Pirfenidone
Active ingredient: Pirfenidone
In short: Pirfenidone tablets are indicated for the treatment of idiopathic pulmonary fibrosis (IPF).
What is Pirfenidone used for?
Pirfenidone tablets are indicated for the treatment of idiopathic pulmonary fibrosis (IPF).
Pirfenidone dosage
Conduct liver function tests prior to initiating treatment with pirfenidone tablets
.
The recommended daily maintenance dosage of pirfenidone tablets is 801 mg three times daily for a total of 2,403 mg/day. Doses should be taken with food at the same time each day.
Upon initiation of treatment, titrate to the full dosage of 2,403 mg/day over a 14-day period as follows:
Table 1. Dosage Titration for pirfenidone tablets in Patients with IPF
Treatment days | Dosage
Days 1 through 7 | 267 mg three times daily (801 mg/day)
Days 8 through 14 | 534 mg three times daily (1,602 mg/day)
Days 15 onward | 801 mg three times daily (2,403 mg/day)
Dosages above 2,403 mg/day are not recommended for any patient. Patients should not take 2 doses at the same time to make up for a missed dose. Patients should not take more than 3 doses per day.
Patients who miss 14 or more days of pirfenidone tablets should re-initiate treatment by undergoing the initial 2-week titration regimen up to the full maintenance dosage
. For treatment interruption of less than 14 days, the dosage prior to the interruption can be resumed.
If patients experience significant adverse reactions (i.e., gastrointestinal, photosensitivity reaction or rash, severe cutaneous adverse reactions (SCAR)), consider temporary dosage reductions orinterruptions of pirfenidone tablets to allow for resolution of symptoms. If a SCAR is confirmed, permanently discontinue pirfenidone tablets
.
Dosage Modification due to Elevated Liver Enzymes
Dosage modifications or interruptions may also be necessary when liver enzyme and bilirubin elevations are exhibited. For liver enzyme elevations, modify the dosage as follows:
If a patient exhibits > 3 but ≤ 5 × the upper limit of normal (ULN) ALT and/or AST without symptoms or hyperbilirubinemia after starting pirfenidone tablets therapy:
Discontinue confounding medications, exclude other causes, and monitor the patient closely.
Repeat liver chemistry tests as clinically indicated.
The full daily dosage may be maintained, if clinically appropriate, or reduced or interrupted (e.g., until liver chemistry tests are within normal limits) with subsequent re-titration to the full dosage as tolerated.
If a patient exhibits > 3 but ≤ 5 × ULN ALT and/or AST accompanied by symptoms or hyperbilirubinemia:
Permanently discontinue pirfenidone tablets.
Do not rechallenge patient with pirfenidone tablets.
If a patient exhibits > 5 × ULN ALT and/or AST:
Permanently discontinue pirfenidone tablets.
Do not rechallenge patient with pirfenidone tablets.
Strong CYP1A2 Inhibitors (e.g., fluvoxamine, enoxacin)
Reduce pirfenidone tablets to 267 mg three times a day (801 mg/day). …
How to take Pirfenidone — instructions & advice from the label
Advise the patient to read the FDA-approved patient labeling (Patient Information).
Liver Enzyme Elevations
Advise patients that they may be required to undergo liver function testing periodically. Instruct patients to immediately report any symptoms of a liver problem (e.g., skin or the white of eyes turn yellow, urine turns dark or brown [tea colored], pain on the right side of stomach, bleed or bruise more easily than normal, lethargy)
.
Photosensitivity Reaction or Rash
Advise patients to avoid or minimize exposure to sunlight (including sunlamps) during use of pirfenidone tablets because of concern for photosensitivity reactions or rash. Instruct patients to use a sunblock and to wear clothing that protects against sun exposure. Instruct patients to report symptoms of photosensitivity reaction or rash to their physician. Temporary dosage reductions or discontinuations may be required
.
Severe Cutaneous Adverse Reactions Advise patients about signs and symptoms of severe cutaneous adverse reactions (SCAR). Advise patients to contact their healthcare provider immediately if they experience signs and symptoms of SCAR
. …
Warnings & precautions
Do not take this medicine if: None.
Cases of drug-induced liver injury (DILI) have been observed with pirfenidone. In the postmarketing period, non-serious and serious cases of DILI, including severe liver injury with fatal outcome, have been reported. Patients treated with pirfenidone 2,403 mg/day in three Phase 3 trials had a higher incidence of elevations in ALT or AST ≥ 3 × ULN than placebo patients (3.7% vs 0.8%, respectively). Elevations ≥ 10 × ULN in ALT or AST occurred in 0.3% of patients in the pirfenidone 2,403 mg/day group and in 0.2% of patients in the placebo group. Increases in ALT and AST ≥ 3 × ULN were reversible with dose modification or treatment discontinuation.
Conduct liver function tests (ALT, AST, and bilirubin) prior to the initiation of therapy with pirfenidone, monthly for the first 6 months, every 3 months thereafter, and as clinically indicated. Measure liver function tests promptly in patients who report symptoms that may indicate liver injury, including fatigue, anorexia, right upper abdominal discomfort, dark urine, or jaundice. Dosage modification or interruption may be necessary for liver enzyme elevations
.
Patients treated with pirfenidone 2,403 mg/day in the three Phase 3 studies had a higher incidence of photosensitivity reactions (9%) compared with patients treated with placebo (1%). The majority of the photosensitivity reactions occurred during the initial 6 months. Instruct patients to avoid or minimize exposure to sunlight (including sunlamps), to use a sunblock (SPF 50 or higher), and to wear clothing that protects against sun exposure. Additionally, instruct patients to avoid concomitant medications known to cause photosensitivity. Dosage reduction or discontinuation may be necessary in some cases of photosensitivity reaction or rash
. …
Pirfenidone side effects
The following adverse reactions are discussed in greater detail in other sections of the labeling:
Liver Enzyme Elevations and Drug-Induced Liver Injury
Photosensitivity Reaction or Rash
Severe Cutaneous Adverse Reactions
Gastrointestinal Disorders
Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice.
The safety of pirfenidone has been evaluated in more than 1,400 subjects with over 170 subjects exposed to pirfenidone for more than 5 years in clinical trials.
Pirfenidone was studied in 3 randomized, double-blind, placebo-controlled trials (Studies 1, 2, and 3) in which a total of 623 patients received 2,403 mg/day of pirfenidone and 624 patients received placebo. Subjects ages ranged from 40 to 80 years (mean age of 67 years). Most patients were male (74%) and Caucasian (95%). The mean duration of exposure to pirfenidone was 62 weeks (range: 2 to 118 weeks) in these 3 trials.
At the recommended dosage of 2,403 mg/day, 14.6% of patients on pirfenidone compared to 9.6% on placebo permanently discontinued treatment because of an adverse event. The most common (> 1%) adverse reactions leading to discontinuation were rash and nausea. …
Drug interactions
Pirfenidone is metabolized primarily (70 to 80%) via CYP1A2 with minor contributions from other CYP isoenzymes including CYP2C9, 2C19, 2D6 and 2E1.
Strong CYP1A2 Inhibitors
The concomitant administration of pirfenidone and fluvoxamine or other strong CYP1A2 inhibitors (e.g., enoxacin) is not recommended because it significantly increases exposure to pirfenidone
. Use of fluvoxamine or other strong CYP1A2 inhibitors should be discontinued prior to administration of pirfenidone and avoided during pirfenidone treatment. In the event that fluvoxamine or other strong CYP1A2 inhibitors are the only drug of choice, dosage reductions are recommended. Monitor for adverse reactions and consider discontinuation of pirfenidone as needed
.
Moderate CYP1A2 Inhibitors
Concomitant administration of pirfenidone and ciprofloxacin (a moderate inhibitor of CYP1A2) moderately increases exposure to pirfenidone
. If ciprofloxacin at the dosage of 750 mg twice daily cannot be avoided, dosage reductions are recommended
. Monitor patients closely when ciprofloxacin is used at a dosage of 250 mg or 500 mg once daily. …
About this medicine
Pirfenidone belongs to the chemical class of pyridone. Pirfenidone tablets are available as film-coated tablets containing 267 mg (yellow) and 801 mg (brown) pirfenidone. Pirfenidone has a molecular formula of C
12H
11NO and a molecular weight of 185.22 g/mol.
Pirfenidone has the following structural formula, which has been referred to as 5-methyl-1Â phenyl-2-1(H)-pyridone or 5-methyl-1-phenyl-2-(1H)-pyridinone.
Pirfenidone is a white to pale yellow, non-hygroscopic powder. It is freely soluble in methanol, ethyl alcohol, acetone and chloroform. Sparingly soluble in 1 N hydrochloric acid, water and 0.1 N sodium hydroxide. The melting point is approximately 106°C to 112°C.
Pirfenidone tablets, USP contain pirfenidone and the following inactive ingredients: colloidal silicon dioxide, ferric ferrous oxide (801 mg only), ferric oxide red (801 mg only), ferric oxide yellow (267 mg only), hydroxypropyl cellulose, magnesium stearate, microcrystalline cellulose, polyethylene glycol, polyvinyl alcohol, sodium starch glycolate, talc and titanium dioxide. …
Source: FDA-approved label via DailyMed (U.S. National Library of Medicine), label set ID 1b3261fe-c066-6e86-e063-6294a90a675c. Read the full official label on DailyMed.